

# MODIFICATION ON FASTING LIPID AND RENAL PARAMETERS IN PATIENTS SWITCHING FROM TENOFOVIR DISOPROXIL TO TENOFOVIR ALAFENAMIDE



P. Taberner Bonastre<sup>1</sup>, L. Vallez Valero<sup>2</sup>, S.M. Cano Marrón<sup>2</sup>, T. Puig Ganau<sup>3</sup>, B. Amoros Folguera<sup>2</sup>, F.I. Torres Bondia<sup>1</sup>, J. A. Schoenenberger<sup>2</sup>

<sup>1</sup>Hospital Universitario Santa Maria, Hospital Pharmacy, Lleida, Spain; <sup>2</sup>Hospital Universitario Arnau de Vilanova de Lleida, Hospital Pharmacy, Lleida, Spain; <sup>3</sup>Hospital Universitario Arnau de Vilanova de Lleida, Infectious Diseases, Lleida, Spain

## J05 - Antivirals for systemic use

### BACKGROUND

Tenofovir alafenamide (TAF) in clinical trials demonstrated less impact than tenofovir disoproxil (TDF) on affecting renal and bone parameters, whereas TDF protects from hypercholesterolemia and hypertriglyceridemia.

### PURPOSE

To analyse how renal function and fasting lipid parameters are modified when switching TDF to TAF. As a second aim, evaluate effectiveness and immunological system.

### METHODS

Retrospective observational study

July 2016 – August 2018

≥6 months  
TDF



TAF >48  
weeks

Virological-success: HIV-1  
RNA <35copies/ml

#### Follow-up variables

- Serum-creatinine, phosphatemia, glomerular filtration rate (GFR)
- Total cholesterol (TC), HDL, LDL, triglycerides
- CD4+, HIV RNA

#### Statistical data (SPSS®)

- 2-sided t-student test for pre-post variables except GFR
- 2-sided Wilcoxon signed-rank test for GFR
- Pearson correlation coefficient for TC, HDL and LDL




### RESULTS

#### Demographic data

48 patients (79,2% men)

44 years (21-70 years)

92% emtricitabine-  
elvitegravir-cobicistat



• Phosphatemia, LDL and TG increased with TAF → No significant differences.

• GFR → No statistical differences.

• Cholesterol correlated with LDL but not with HDL.

• All patients achieved virological-success.

### CONCLUSION

After 48 weeks of patients, in clinical practice, who just changed TAF on their ART, 100% of patients archived virological-suppression, with reduction of serum-creatinine and improvement immunological system, nevertheless hypercholesterolemia was observed based mainly on LDL elevation.